Trials / Terminated
TerminatedNCT00308464
A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency
A Double Blind Parallel Group Randomised Multiple Dose Study To Evaluate The Pharmacodynamic Response And Safety Of PHA-794428 In Adult Growth Hormone Deficient Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the safety, toleration and dose response of PHA-794428 after multiple weekly injections in male and female growth hormone deficient patients.
Detailed description
The study terminated on 10-Dec-2007. Pfizer's decision to terminate the program was due to cases of injection-site lipoatrophy that were reported in the clinical Phase 2 studies after a single injection of PHA 794428.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PHA-794428 |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2006-03-29
- Last updated
- 2011-05-18
Locations
35 sites across 12 countries: Belgium, Czechia, Denmark, France, Germany, Italy, Netherlands, Poland, Slovakia, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00308464. Inclusion in this directory is not an endorsement.